Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide and remains a significant cause of inherited blindness.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- FDA Accepts Aldeyra’s Reproxalap Application for Review
- Aldeyra announces FDA acceptance for review of reproxalap NDA
- Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion
- Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191
- Aldeyra receives special protocol assessment agreement letter from FDA